HNSCC
MCID: OBS525
MIFTS: 57

Obsolete: Squamous Cell Carcinoma of Head and Neck (HNSCC)

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Obsolete: Squamous Cell Carcinoma of Head and Neck

MalaCards integrated aliases for Obsolete: Squamous Cell Carcinoma of Head and Neck:

Name: Obsolete: Squamous Cell Carcinoma of Head and Neck 58
Head and Neck Squamous Cell Carcinoma 58
Hnscc 58

Characteristics:

Orphanet epidemiological data:

58
obsolete: squamous cell carcinoma of head and neck
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: All ages;

Classifications:



External Ids:

Orphanet 58 ORPHA67037

Summaries for Obsolete: Squamous Cell Carcinoma of Head and Neck

MalaCards based summary : Obsolete: Squamous Cell Carcinoma of Head and Neck, also known as head and neck squamous cell carcinoma, is related to oropharynx cancer and squamous cell papilloma. An important gene associated with Obsolete: Squamous Cell Carcinoma of Head and Neck is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Cevimeline and Raltitrexed have been mentioned in the context of this disorder. Affiliated tissues include lymph node, lung and t cells, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Obsolete: Squamous Cell Carcinoma of Head and Neck

Diseases related to Obsolete: Squamous Cell Carcinoma of Head and Neck via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 481)
# Related Disease Score Top Affiliating Genes
1 oropharynx cancer 31.9 TP53 PTEN PIK3CA HRAS EGFR
2 squamous cell papilloma 31.6 TP53 HRAS
3 papilloma 30.7 TP53 PTEN FGFR3 EGFR
4 skin melanoma 30.6 TP53 HRAS BRAF
5 breast squamous cell carcinoma 30.5 TP53 PIK3CA HRAS
6 in situ carcinoma 30.4 TP53 PTEN HRAS EGFR
7 soft tissue sarcoma 30.4 TP53 EGFR
8 acneiform dermatitis 30.4 HRAS EGFR
9 verrucous carcinoma 30.2 TP53 PTEN EGFR
10 lung benign neoplasm 30.1 TP53 HRAS EGFR
11 retinitis pigmentosa 11 30.1 TP53 PTEN HRAS EGFR
12 thymoma 30.1 TP53 PIK3CA HRAS EGFR
13 pleomorphic adenoma 30.1 TP53 HRAS CTNNB1
14 small cell carcinoma 29.9 TP53 PTEN EGFR
15 tongue cancer 29.9 TP53 PTEN EGFR CTNNB1
16 oral cavity cancer 29.9 TP53 TNFRSF10B PTEN PIK3CA EGFR
17 paronychia 29.8 HRAS EGFR
18 laryngeal squamous cell carcinoma 29.8 TP53 PTEN EGFR
19 thyroid tumor 29.8 TP53 PTEN PIK3CA HRAS BRAF
20 keratosis 29.7 TP53 PIK3CA HRAS FGFR3 EGFR
21 skin squamous cell carcinoma 29.6 TP53 PTEN HRAS EGFR BRAF
22 t-cell leukemia 29.6 TP53 SMAD4 PTEN PIK3CA HRAS
23 adenosquamous carcinoma 29.4 TP53 SMAD4 PTEN PIK3CA EGFR
24 gastrointestinal stromal tumor 29.4 TP53 PTEN FGFR3 EGFR BRAF
25 glioma 29.4 TP53 PTEN PIK3CA IDH2 EGFR BRAF
26 bladder cancer 29.4 TP53 PTEN PIK3CA HRAS FGFR3 EGFR
27 cervical squamous cell carcinoma 29.3 TP53 PIK3CA EGFR CTNNB1
28 malignant glioma 29.3 TP53 TNFRSF10B PTEN EGFR
29 leukemia, chronic lymphocytic 29.3 TP53 PTEN HRAS EGFR BRAF
30 thyroid carcinoma 29.2 TP53 PTEN PIK3CA HRAS CTNNB1 BRAF
31 tongue squamous cell carcinoma 29.0 TP53 PTEN EGFR CTNNB1
32 adenoma 29.0 TP53 SMAD4 PIK3CA GNAS CTNNB1 BRAF
33 leukemia, chronic myeloid 28.9 TP53 TNFRSF10B PTEN HRAS EGFR
34 glioma susceptibility 1 28.8 TP53 PTEN PIK3CA IDH2 HRAS EGFR
35 familial adenomatous polyposis 28.6 TP53 TNFRSF10B SMAD4 HRAS CTNNB1
36 esophageal cancer 28.6 TP53 SMAD4 PTEN PIK3CA HRAS EGFR
37 adenoid cystic carcinoma 28.5 TP53 PTEN PIK3CA HRAS EGFR CTNNB1
38 colorectal adenocarcinoma 28.5 TP53 PTEN HRAS EGFR CTNNB1 BRAF
39 renal cell carcinoma, nonpapillary 28.4 TP53 TNFRSF10B PTEN PIK3CA HRAS EGFR
40 colon adenocarcinoma 28.2 TP53 SMAD4 PTEN PIK3CA EGFR CTNNB1
41 squamous cell carcinoma, head and neck 28.2 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
42 lung squamous cell carcinoma 28.1 TP53 PTEN PIK3CA NFE2L2 HRAS FGFR3
43 leukemia, acute myeloid 27.9 TP53 TNFRSF10B PTEN IDH2 HRAS EGFR
44 nasopharyngeal carcinoma 27.9 TP53 SMAD4 PTEN PIK3CA HRAS EGFR
45 glioblastoma multiforme 27.7 TP53 TNFRSF10B PTEN PIK3CA IDH2 HRAS
46 endometrial cancer 27.6 TP53 SMAD4 PTEN PIK3CA HRAS EGFR
47 myeloma, multiple 27.5 TP53 TNFRSF10B PTEN IDH2 HRAS FGFR3
48 gastric cancer 27.5 TP53 SMAD4 PTEN PIK3CA NFE2L2 HRAS
49 adenocarcinoma 27.4 TP53 SMAD4 PTEN PIK3CA HRAS GNAS
50 squamous cell carcinoma 27.2 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2

Graphical network of the top 20 diseases related to Obsolete: Squamous Cell Carcinoma of Head and Neck:



Diseases related to Obsolete: Squamous Cell Carcinoma of Head and Neck

Symptoms & Phenotypes for Obsolete: Squamous Cell Carcinoma of Head and Neck

GenomeRNAi Phenotypes related to Obsolete: Squamous Cell Carcinoma of Head and Neck according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.3 BRAF EGFR HRAS PIK3CA
2 Decreased viability GR00221-A-1 10.3 EGFR HRAS PIK3CA
3 Decreased viability GR00221-A-2 10.3 HRAS PIK3CA
4 Decreased viability GR00221-A-3 10.3 HRAS
5 Decreased viability GR00221-A-4 10.3 BRAF EGFR PIK3CA
6 Decreased viability GR00301-A 10.3 BRAF
7 Decreased viability GR00381-A-1 10.3 BRAF
8 Decreased viability GR00402-S-2 10.3 BRAF EGFR HRAS PIK3CA
9 Decreased viability in esophageal squamous lineage GR00235-A 10.03 BRAF CTNNB1 FGFR3 GNAS HRAS IDH2
10 Decreased cell migration GR00055-A-1 9.98 BRAF CTNNB1 EGFR FGFR3 HRAS MAP2K2
11 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.8 CTNNB1 EGFR FGFR3 HRAS PTEN
12 Increased cell death HMECs cells GR00103-A-0 9.63 CTNNB1 EGFR MAP2K2 PIK3CA PTEN TP53
13 Decreased sensitivity to paclitaxel GR00112-A-0 9.37 PTEN SMAD4
14 Increased cell migration GR00055-A-3 9.35 BRAF CTNNB1 EGFR HRAS PIK3CA
15 Reduced mammosphere formation GR00396-S 9.23 BRAF EGFR GNAS HRAS IDH2 NFE2L2

MGI Mouse Phenotypes related to Obsolete: Squamous Cell Carcinoma of Head and Neck:

45 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.41 BRAF CTNNB1 FGFR3 GNAS HRAS ING1
2 cardiovascular system MP:0005385 10.41 BRAF CTNNB1 EGFR GNAS HRAS IDH2
3 cellular MP:0005384 10.4 BRAF CTNNB1 EGFR FGFR3 GNAS ING1
4 growth/size/body region MP:0005378 10.4 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
5 homeostasis/metabolism MP:0005376 10.38 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
6 endocrine/exocrine gland MP:0005379 10.34 BRAF CTNNB1 EGFR GNAS HRAS ING1
7 integument MP:0010771 10.33 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
8 craniofacial MP:0005382 10.32 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
9 mortality/aging MP:0010768 10.32 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
10 neoplasm MP:0002006 10.32 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
11 digestive/alimentary MP:0005381 10.31 BRAF CTNNB1 EGFR FGFR3 HRAS MAP2K2
12 immune system MP:0005387 10.3 BRAF CTNNB1 EGFR FGFR3 GNAS ING1
13 hematopoietic system MP:0005397 10.27 BRAF CTNNB1 EGFR FGFR3 GNAS ING1
14 adipose tissue MP:0005375 10.24 BRAF EGFR GNAS MAP2K2 NFE2L2 PIK3CA
15 embryo MP:0005380 10.21 BRAF CTNNB1 EGFR NFE2L2 PIK3CA PTEN
16 nervous system MP:0003631 10.2 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
17 limbs/digits/tail MP:0005371 10.19 BRAF CTNNB1 EGFR FGFR3 GNAS IDH2
18 normal MP:0002873 10.14 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
19 hearing/vestibular/ear MP:0005377 10.13 BRAF CTNNB1 EGFR FGFR3 GNAS MAP2K2
20 liver/biliary system MP:0005370 10.13 BRAF CTNNB1 EGFR GNAS NFE2L2 PTEN
21 muscle MP:0005369 10.1 BRAF CTNNB1 EGFR GNAS PIK3CA PTEN
22 renal/urinary system MP:0005367 10.02 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
23 no phenotypic analysis MP:0003012 9.98 CTNNB1 EGFR FGFR3 GNAS HRAS PIK3CA
24 reproductive system MP:0005389 9.86 BRAF CTNNB1 EGFR FGFR3 PIK3CA PTEN
25 respiratory system MP:0005388 9.81 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
26 pigmentation MP:0001186 9.77 BRAF CTNNB1 EGFR PTEN TP53
27 skeleton MP:0005390 9.77 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
28 vision/eye MP:0005391 9.23 BRAF CTNNB1 EGFR FGFR3 MAP2K2 PIK3CA

Drugs & Therapeutics for Obsolete: Squamous Cell Carcinoma of Head and Neck

Drugs for Obsolete: Squamous Cell Carcinoma of Head and Neck (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 310)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cevimeline Approved Phase 4 107233-08-9 83898 25137844
2
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758
3 Muscarinic Agonists Phase 4
4 Cholinergic Agents Phase 4
5
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
6
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
7
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
8
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
9
Dapsone Approved, Investigational Phase 3 80-08-0 2955
10
Metformin Approved Phase 3 657-24-9 4091 14219
11
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
12
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
13
leucovorin Approved Phase 3 58-05-9 6006 143
14
Bevacizumab Approved, Investigational Phase 3 216974-75-3
15
Lenvatinib Approved, Investigational Phase 3 417716-92-8
16
Durvalumab Approved, Investigational Phase 3 1428935-60-7
17
afatinib Approved Phase 3 439081-18-2, 850140-72-6 10184653
18
Edetic Acid Approved, Vet_approved Phase 3 62-33-9, 60-00-4 6049
19
Pentetic acid Approved Phase 3 67-43-6
20
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
21
Melatonin Approved, Nutraceutical, Vet_approved Phase 3 73-31-4 896
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
23
Tirapazamine Investigational Phase 3 27314-97-2
24
Zalutumumab Investigational Phase 3 828933-61-3, 667901-13-5
25 Tocotrienol Investigational Phase 3 6829-55-6
26
Nimotuzumab Investigational Phase 3 828933-61-3, 780758-10-3
27 Nimorazole Investigational Phase 3 6506-37-2
28 Endostatins Phase 3 71581480
29 Protective Agents Phase 3
30 interferons Phase 3
31 Central Nervous System Depressants Phase 3
32 Interferon-alpha Phase 3
33 Antioxidants Phase 3
34 Antimalarials Phase 3
35 Antitubercular Agents Phase 3
36 Tocopherols Phase 3
37 Tocotrienols Phase 3
38 Deoxyglucose Phase 3
39 Hypoglycemic Agents Phase 3
40 Lugol's solution Phase 3
41 Antimitotic Agents Phase 3
42 Mitogens Phase 3
43 Folic Acid Antagonists Phase 3
44 Vitamin B Complex Phase 3
45 Vitamin B9 Phase 3
46 Folate Phase 3
47 Immunoglobulin G Phase 3
48 Angiogenesis Inhibitors Phase 3
49 Endothelial Growth Factors Phase 3
50 Pharmaceutical Solutions Phase 3

Interventional clinical trials:

(show top 50) (show all 626)
# Name Status NCT ID Phase Drugs
1 Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer Completed NCT03998696 Phase 4 Cisplatin 40 mg/m2;Cisplatin 100 mg/m2
2 An Investigator-Initiated,Multicenter,Randomized,Double-Blind Placebo-Controlled Design Study to Assess the Effectiveness of CeviMeline to Improve OraL Health in Patients With XErostomia Secondary to Radiation Therapy for Treatment of Head and Neck Squamous Cell Carcinoma Completed NCT00466388 Phase 4 Cevimeline
3 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial Recruiting NCT03196843 Phase 4 Raltitrexed
4 Randomised Clinical Phase III Study of Radiotherapy Dose, Volume Evaluation for 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Squamous Cell Carcinoma Unknown status NCT01124409 Phase 3
5 DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification With Nimorazole During Radiotherapy/Chemoradiotherapy of Squamous Cell Carcinoma of the Head and Neck. Unknown status NCT02661152 Phase 3 Nimorazole
6 A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
7 A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer Unknown status NCT00720070 Phase 3
8 A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy Completed NCT01345682 Phase 3 Afatinib;Methotrexate
9 Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma Completed NCT00158652 Phase 3 5FU, Paraplatin
10 A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
11 Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer Completed NCT00174837 Phase 3 Tirapazamine;Cisplatin
12 A Phase III Randomised, Stratified, Parallel-Group, Multi-Centre, Comparative Study of ZD1839 (Iressa®) 250 Mg and 500 Mg Versus Methotrexate for Previously Treated Patients With Squamous Cell Carcinoma of the Head and Neck Completed NCT00206219 Phase 3 Gefitinib;methotrexate
13 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
14 DAHANCA 19: A Randomized Study of the Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck Completed NCT00496652 Phase 3 Zalutumumab
15 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
16 Phase III Randomized Study of Adjuvant Biologic Therapy in Patients With Stages III/IV Head and Neck Squamous Cell Carcinoma Completed NCT00054561 Phase 3 isotretinoin
17 Neoadjuvant Docetaxel+Cisplatin and 5-fluorouracil (TPF) Followed by Radiotherapy+Concomitant Chemo or Cetuximab Versus Radiotherapy+Concomitant Chemo or Cetuximab in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Randomized Phase III Factorial Study. Completed NCT01086826 Phase 3 RT+CDDP/5-FU;RT+CETUXIMAB;INDUCTION CTx(TPF)+(RT+CDDP/5-FU);INDUCTION CTx(TPF)+(RT+CETUXIMAB)
18 Randomized, Double-blind, Multicenter Two-Stage Adaptive Phase 3 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin Versus the Chemotherapy Alone in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Who Have Progressed on or After Prior Platinum-Based Chemotherapy Completed NCT01166542 Phase 3 Carboplatin;Paclitaxel;Placebo
19 Phase III Study Of Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
20 A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Completed NCT01931150 Phase 3 Topical Dapsone 5% Gel;oral antibiotics
21 Effect of Melatonin in Combination With Neoadjuvant Chemotherapy to HIF-1⍺, CD44, CD133, and miR-210 Expression and Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma (OSCC) Completed NCT04137627 Phase 3 Melatonin 20 MG Oral Capsule;Placebo oral capsule
22 Postoperative Radiation and Concurrent Chemotherapy With Weekly Docetaxel Versus Cisplatin in Patients With High Risk Squamous Cell Carcinoma of Head & Neck: a Randomized Multi-center Phase III Clinical Trial Recruiting NCT02923258 Phase 2, Phase 3 Docetaxel;Cisplatinum
23 A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Recruiting NCT04128696 Phase 3 GSK3359609;Pembrolizumab;Placebo
24 A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC) Recruiting NCT03765918 Phase 3 Cisplatin 100 mg/m^2
25 Multicenter Randomized Controlled Phase III Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy Recruiting NCT03700905 Phase 3 Neoadjuvant Nivolumab;Adjuvant Nivolumab;Adjuvant Nivolumab and Ipilimumab
26 Phase 3 Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Standard of Care for Locoregional Recurrent Head/Neck Squamous Cell Carcinoma in Patients Who Have Failed After at Least Two Lines of Therapy Recruiting NCT03769506 Phase 3 Physician's Choice SOC
27 A Phase 3, Randomized, Open-label Clinical Trial of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Recruiting NCT03815903 Phase 3 Induction chemotherapy
28 Randomized Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma Recruiting NCT03519048 Phase 3
29 Definitive Chemo-Radiotherapy With or Without Up-front Neck Dissection for Regionally Advanced Head and Neck Squamous Cell Carcinoma: A Phase III Multi-center Prospective Randomized Controlled Trial With Two Additional Observational Cohorts Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)
30 Uniform FDG‐PET Guided GRAdient Dose prEscription to Reduce Late Radiation Toxicity (UPGRADE‐RT): a Randomised Controlled Trial With Dose Reduction to the Elective Neck in Head and Neck Squamous Cell Carcinoma Recruiting NCT02442375 Phase 3
31 Multicenter, Randomized, Double-blind, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of TQB2450 Plus Chemotherapy(Cisplatin or Carboplatin+ 5-Fluorouracil (5-FU) ) Versus Placebo Plus Chemotherapy as First-Line Treatment in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(R/M SCCHN) Recruiting NCT03855384 Phase 3 TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU);placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
32 Phase III Trial of Laryngeal Preservation Comparing Induction Chemotherapy With Cisplatin, 5-fluorouracil and Docetaxel (TPF) Followed by Radiotherapy and Concomitant Administration of Radiotherapy With Cisplatin Recruiting NCT03340896 Phase 3 Docetaxel;Cisplatin;Fluorouracil
33 A Phase II/III Trial of Comparison of Benefit of Administration of Keytruda Via Artery or Fine Needle to Tumor Versus Vein for Immunotherapy of Advanced Solid Tumors Recruiting NCT03755739 Phase 2, Phase 3 Pembrolizumab
34 Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head & Neck Squamous Cell Cancer Recruiting NCT00957086 Phase 3 Nimotuzumab;Placebo
35 A Phase III Randomized Trial of Avelumab-cetuximab-Radiotherapy Versus Standards of Care in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Recruiting NCT02999087 Phase 3 Cetuximab;avelumab;Cisplatin
36 A Phase III Randomized Study of Chemo-radiotherapy Versus Radiotherapy Alone in the Adjuvant Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy) Recruiting NCT02998385 Phase 3 Cisplatin
37 Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomized Clinical Trial (Part 1) Recruiting NCT03685409 Phase 3 Metformin Hydrochloride 500 MG;Placebo Oral Tablet
38 Non Inferiority Randomized Trial of Standard Radiotherapy Versus Hypofractionated Split Course Radiotherapy in Elderly Vulnerable Patients With Inoperable Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT01864850 Phase 3
39 A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) Active, not recruiting NCT03358472 Phase 3 Pembrolizumab;Epacadostat;Cetuximab;Cisplatin;Carboplatin;5-Fluorouracil
40 A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412) Active, not recruiting NCT03040999 Phase 3 Placebo;Cisplatin
41 A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) Active, not recruiting NCT01950689 Phase 3 Nimorazole
42 A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT02358031 Phase 3 Cisplatin;Carboplatin;5-FU
43 A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy. Active, not recruiting NCT01856478 Phase 3 methotrexate;afatinib
44 A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02 Active, not recruiting NCT01427478 Phase 3 AFATINIB;Placebo of AFATINIB
45 A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
46 Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00158678 Phase 3 concomitant cisplatin
47 Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux Active, not recruiting NCT00609284 Phase 3 cetuximab;Carboplatin, 5FU concomitant
48 Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation Active, not recruiting NCT01884623 Phase 3 Cetuximab;Methotrexate
49 A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT02252042 Phase 3 methotrexate;docetaxel
50 Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin Active, not recruiting NCT00999700 Phase 3 docetaxel - cisplatin - 5-fluorouracil;cetuximab;cisplatin

Search NIH Clinical Center for Obsolete: Squamous Cell Carcinoma of Head and Neck

Genetic Tests for Obsolete: Squamous Cell Carcinoma of Head and Neck

Anatomical Context for Obsolete: Squamous Cell Carcinoma of Head and Neck

MalaCards organs/tissues related to Obsolete: Squamous Cell Carcinoma of Head and Neck:

40
Lymph Node, Lung, T Cells, Endothelial, Testes, Tongue, Salivary Gland

Publications for Obsolete: Squamous Cell Carcinoma of Head and Neck

Articles related to Obsolete: Squamous Cell Carcinoma of Head and Neck:

(show top 50) (show all 7496)
# Title Authors PMID Year
1
Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. 6 61
11801303 2002
2
Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. 6
10866301 2000
3
Rare loss-of-function mutation of a death receptor gene in head and neck cancer. 6
9721851 1998
4
Radiosensitization approaches for HPV-positive and HPV-negative head and neck squamous carcinomas. 61
31283004 2020
5
Identification of new hypoxia-regulated epithelial-mesenchymal transition marker genes labeled by H3K4 acetylation. 61
31408253 2020
6
Diagnosis, Staging, Radiation Treatment Response Assessment, and Outcome Prognostication of Head and Neck Cancers Using PET Imaging: A Systematic Review. 61
31735303 2020
7
Nucleolin mediates the binding of cancer cells to L-selectin under conditions of lymphodynamic shear stress. 61
31644306 2020
8
Radiation-induced nausea and vomiting in head and neck cancer: Is it something worth considering in the intensity modulated radiotherapy era? "A narrative review". 61
31633260 2020
9
Distant Intramuscular Metastases of Head and Neck Squamous Cell Carcinoma. 61
31833883 2020
10
The transcription factor FOXM1 regulates the balance between proliferation and aberrant differentiation in head and neck squamous cell carcinoma. 61
31465124 2020
11
Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma. 61
31765738 2020
12
RNA-Seq analysis of peripheral blood mononuclear cells reveals unique transcriptional signatures associated with radiotherapy response of nasopharyngeal carcinoma and prognosis of head and neck cancer. 61
31698994 2020
13
Knockdown of LINC01116 inhibits cell migration and invasion in head and neck squamous cell carcinoma through epithelial-mesenchymal transition pathway. 61
31452270 2020
14
Immunotherapy in head and neck cancer: The great challenge of patient selection. 61
31739116 2019
15
Regulatory T cells induce CD4- NKT cell anergy and suppress NKT cell cytotoxic function. 61
31641795 2019
16
EORTC Quality of Life Questionnaire Head and Neck (H&N)-35 scores from H&N squamous cell carcinoma patients obtained at diagnosis and at 6, 9 and 12 months following diagnosis predict 10-year overall survival. 61
31529149 2019
17
Optimal mass transport kinetic modeling for head and neck DCE-MRI: Initial analysis. 61
31273818 2019
18
MT4-MMP promotes invadopodia formation and cell motility in FaDu head and neck cancer cells. 61
31813546 2019
19
Hippo Pathway and YAP Signaling Alterations in Squamous Cancer of the Head and Neck. 61
31817001 2019
20
[Immunotherapy for head and neck cancer : Highlights of the 2019 ASCO Annual Meeting]. 61
31612261 2019
21
Somatic mitochondrial mutation discovery using ultra-deep sequencing of the mitochondrial genome reveals spatial tumor heterogeneity in head and neck squamous cell carcinoma. 61
31830557 2019
22
Mutation signature analysis identifies increased mutation caused by tobacco smoke associated DNA adducts in larynx squamous cell carcinoma compared with oral cavity and oropharynx. 61
31848367 2019
23
Assessment of cancer stem cell marker expression in primary head and neck squamous cell carcinoma shows prognostic value for aldehyde dehydrogenase (ALDH1A1). 61
31811857 2019
24
Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMT and confers resistance to the EGFR inhibitor erlotinib. 61
31838083 2019
25
ACLY (ATP Citrate Lyase) Mediates Radioresistance in Head and Neck Squamous Cell Carcinomas and is a Novel Predictive Radiotherapy Biomarker. 61
31817870 2019
26
Tumor necrosis factor-α triggers opposing signals in head and neck squamous cell carcinoma and induces apoptosis via mitochondrial- and non-mitochondrial-dependent pathways. 61
31638203 2019
27
Metabolic imaging using hyperpolarized pyruvate-lactate exchange assesses response or resistance to the EGFR inhibitor cetuximab in patient-derived HNSCC xenografts. 61
31831557 2019
28
G-protein coupled receptor kinase 2 safeguards epithelial phenotype in Head and Neck Squamous Cell Carcinomas. 61
31850518 2019
29
Jumonji domain-containing protein 6 functions as a marker of head and neck squamous cell carcinoma at advanced stage with no effect on prognosis. 61
31788057 2019
30
An update: circulating tumor cells in head and neck cancer. 61
31680565 2019
31
Dynamic factors affecting HPV-attributable fraction for head and neck cancers. 61
31465959 2019
32
Ammonium tetrathiomolybdate enhances the antitumor effect of cisplatin via the suppression of ATPase copper transporting beta in head and neck squamous cell carcinoma. 61
31638244 2019
33
Immunotherapy orchestrates radiotherapy in composing abscopal effects: A strategic review in metastatic head and neck cancer. 61
31834023 2019
34
Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma. 61
31805962 2019
35
Immunotherapy for head and neck cancer: Recent advances and future directions. 61
31683169 2019
36
Associations between expression levels of nine core nucleotide excision repair genes in lymphocytes and risk of head and neck squamous cell carcinomas in a Chinese population. 61
31832883 2019
37
MiR-381-3p suppresses biological characteristics of cancer in head-neck squamous cell carcinoma cells by targeting nuclear autoantigenic sperm protein (NASP). 61
31797734 2019
38
MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma. 61
31800160 2019
39
Single-cell sequencing and its applications in head and neck cancer. 61
31689639 2019
40
Development and validation of a novel and rapid molecular detection method for high-risk HPV in formalin-fixed paraffin-embedded tumor tissue. 61
31837430 2019
41
HPV16 E5 Mediates Resistance to PD-L1 Blockade and can be targeted with Rimantadine in Head and Neck Cancer. 61
31848196 2019
42
Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study. 61
31831042 2019
43
EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling. 61
31661464 2019
44
Hypoxic niches are endowed with a protumorigenic mechanism that supersedes the protective function of PTEN. 61
31560860 2019
45
Predictive Value of First Posttreatment Imaging Using Standardized Reporting in Head and Neck Cancer. 61
31331239 2019
46
Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy. 61
31439582 2019
47
Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer. 61
31135957 2019
48
Antibody Responses to Cancer Antigens Identify Patients with a Poor Prognosis among HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Patients. 61
31444248 2019
49
Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status. 61
31407331 2019
50
CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models. 61
31827111 2019

Variations for Obsolete: Squamous Cell Carcinoma of Head and Neck

ClinVar genetic disease variations for Obsolete: Squamous Cell Carcinoma of Head and Neck:

6 (show top 50) (show all 344) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 EGFR NM_005228.5(EGFR):c.2155G>C (p.Gly719Arg)SNV Likely pathogenic,drug response 45224 rs28929495 7:55241707-55241707 7:55174014-55174014
2 TP53 NM_000546.5(TP53):c.832C>A (p.Pro278Thr)SNV Likely pathogenic,drug response 376643 rs17849781 17:7577106-7577106 17:7673788-7673788
3 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
4 TP53 NM_000546.5(TP53):c.517G>T (p.Val173Leu)SNV Pathogenic 376668 rs876660754 17:7578413-7578413 17:7675095-7675095
5 TP53 NM_000546.5(TP53):c.537T>G (p.His179Gln)SNV Pathogenic 376607 rs876660821 17:7578393-7578393 17:7675075-7675075
6 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg)SNV Pathogenic 45466 rs397517201 3:178936095-178936095 3:179218307-179218307
7 TNFRSF10B TNFRSF10B, 2-BP INSinsertion Pathogenic 6194
8 PTEN NM_001304718.2(PTEN):c.-389C>GSNV Pathogenic 7842 rs121909237 10:89692878-89692878 10:87933121-87933121
9 MAP2K2 NM_030662.3(MAP2K2):c.169T>G (p.Phe57Val)SNV Pathogenic 8273 rs121434498 19:4117551-4117551 19:4117553-4117553
10 SMAD4 NM_005359.5(SMAD4):c.1081C>T (p.Arg361Cys)SNV Pathogenic 8543 rs80338963 18:48591918-48591918 18:51065548-51065548
11 IDH2 NM_002168.3(IDH2):c.419G>A (p.Arg140Gln)SNV Pathogenic 14716 rs121913502 15:90631934-90631934 15:90088702-90088702
12 FGFR3 NM_000142.4(FGFR3):c.742C>T (p.Arg248Cys)SNV Pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
13 FGFR3 NM_000142.4(FGFR3):c.746C>G (p.Ser249Cys)SNV Pathogenic 16339 rs121913483 4:1803568-1803568 4:1801841-1801841
14 SMAD4 NM_005359.5(SMAD4):c.1082G>A (p.Arg361His)SNV Pathogenic 24832 rs377767347 18:48591919-48591919 18:51065549-51065549
15 TP53 NM_000546.5(TP53):c.422G>A (p.Cys141Tyr)SNV Pathogenic 140801 rs587781288 17:7578508-7578508 17:7675190-7675190
16 TP53 NM_000546.5(TP53):c.706T>G (p.Tyr236Asp)SNV Pathogenic 142183 rs587782289 17:7577575-7577575 17:7674257-7674257
17 TP53 NM_000546.5(TP53):c.833C>T (p.Pro278Leu)SNV Pathogenic 232497 rs876659802 17:7577105-7577105 17:7673787-7673787
18 PIK3CA NM_006218.4(PIK3CA):c.2176G>A (p.Glu726Lys)SNV Pathogenic 376476 rs867262025 3:178938934-178938934 3:179221146-179221146
19 TP53 NM_000546.5(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
20 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
21 TP53 NM_000546.5(TP53):c.712T>C (p.Cys238Arg)SNV Pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
22 TP53 NM_000546.5(TP53):c.713G>T (p.Cys238Phe)SNV Pathogenic 376574 rs730882005 17:7577568-7577568 17:7674250-7674250
23 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
24 TP53 NM_000546.5(TP53):c.584T>C (p.Ile195Thr)SNV Pathogenic 216077 rs760043106 17:7578265-7578265 17:7674947-7674947
25 TP53 NM_000546.5(TP53):c.856G>A (p.Glu286Lys)SNV Pathogenic 183752 rs786201059 17:7577082-7577082 17:7673764-7673764
26 TP53 NM_000546.5(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
27 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
28 TP53 NM_000546.5(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
29 TP53 NM_000546.5(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
30 TP53 NM_000546.5(TP53):c.488A>G (p.Tyr163Cys)SNV Pathogenic 127814 rs148924904 17:7578442-7578442 17:7675124-7675124
31 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
32 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu)SNV Pathogenic 13961 rs113488022 7:140453136-140453136 7:140753336-140753336
33 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
34 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
35 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
36 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
37 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
38 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
39 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
40 TP53 NM_000546.5(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
41 TP53 NM_000546.5(TP53):c.734G>A (p.Gly245Asp)SNV Pathogenic 12355 rs121912656 17:7577547-7577547 17:7674229-7674229
42 TP53 NM_000546.5(TP53):c.725G>A (p.Cys242Tyr)SNV Pathogenic 12354 rs121912655 17:7577556-7577556 17:7674238-7674238
43 TP53 NM_000546.5(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
44 TP53 NM_000546.5(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
45 ING1 NM_198217.2(ING1):c.443C>A (p.Ala148Asp)SNV Pathogenic 8069 rs121909252 13:111372014-111372014 13:110719667-110719667
46 ING1 NM_198217.2(ING1):c.515A>G (p.Asn172Ser)SNV Pathogenic 8068 rs121909251 13:111372086-111372086 13:110719739-110719739
47 ING1 NM_198217.2(ING1):c.512G>C (p.Cys171Ser)SNV Pathogenic 8067 rs121909250 13:111372083-111372083 13:110719736-110719736
48 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln)SNV Pathogenic 7829 rs121909229 10:89692905-89692905 10:87933148-87933148
49 BRAF NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly)SNV Pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354
50 TP53 NM_000546.5(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230

Expression for Obsolete: Squamous Cell Carcinoma of Head and Neck

Search GEO for disease gene expression data for Obsolete: Squamous Cell Carcinoma of Head and Neck.

Pathways for Obsolete: Squamous Cell Carcinoma of Head and Neck

Pathways related to Obsolete: Squamous Cell Carcinoma of Head and Neck according to GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.22 TP53 TNFRSF10B SMAD4 PTEN PIK3CA MAP2K2
2
Show member pathways
13.91 TP53 TNFRSF10B PTEN MAP2K2 HRAS GNAS
3
Show member pathways
13.87 TP53 TNFRSF10B SMAD4 PTEN MAP2K2 HRAS
4
Show member pathways
13.77 SMAD4 PIK3CA MAP2K2 HRAS FGFR3 EGFR
5
Show member pathways
13.77 TP53 SMAD4 MAP2K2 HRAS GNAS FGFR3
6
Show member pathways
13.75 TP53 TNFRSF10B SMAD4 MAP2K2 HRAS GNAS
7
Show member pathways
13.64 SMAD4 MAP2K2 HRAS GNAS FGFR3 EGFR
8
Show member pathways
13.61 TP53 TNFRSF10B SMAD4 PIK3CA MAP2K2 HRAS
9
Show member pathways
13.58 SMAD4 PIK3CA MAP2K2 HRAS FGFR3 EGFR
10
Show member pathways
13.48 TP53 TNFRSF10B PTEN HRAS GNAS FGFR3
11
Show member pathways
13.48 PTEN PIK3CA MAP2K2 HRAS GNAS EGFR
12
Show member pathways
13.44 TP53 PIK3CA MAP2K2 HRAS FGFR3 EGFR
13
Show member pathways
13.38 TNFRSF10B SMAD4 PTEN HRAS FGFR3 EGFR
14
Show member pathways
13.37 PTEN MAP2K2 HRAS GNAS FGFR3 EGFR
15
Show member pathways
13.36 MAP2K2 HRAS GNAS FGFR3 EGFR CTNNB1
16
Show member pathways
13.3 TP53 PTEN MAP2K2 HRAS GNAS EGFR
17
Show member pathways
13.21 TP53 SMAD4 PIK3CA MAP2K2 HRAS GNAS
18
Show member pathways
13.15 TP53 PTEN MAP2K2 HRAS GNAS FGFR3
19
Show member pathways
13.12 MAP2K2 HRAS GNAS EGFR CTNNB1 BRAF
20
Show member pathways
13.08 TP53 MAP2K2 HRAS GNAS CTNNB1 BRAF
21
Show member pathways
13.04 TP53 PIK3CA MAP2K2 HRAS GNAS EGFR
22
Show member pathways
13.04 TP53 TNFRSF10B PTEN PIK3CA MAP2K2 HRAS
23
Show member pathways
13.04 TP53 PTEN PIK3CA MAP2K2 HRAS GNAS
24
Show member pathways
13 PTEN PIK3CA MAP2K2 HRAS EGFR BRAF
25
Show member pathways
13 PTEN PIK3CA MAP2K2 HRAS EGFR CTNNB1
26
Show member pathways
12.99 MAP2K2 HRAS GNAS EGFR CTNNB1 BRAF
27
Show member pathways
12.98 PTEN MAP2K2 HRAS CTNNB1 BRAF
28
Show member pathways
12.98 PTEN PIK3CA MAP2K2 HRAS GNAS FGFR3
29
Show member pathways
12.93 PIK3CA MAP2K2 HRAS EGFR BRAF
30
Show member pathways
12.9 TP53 TNFRSF10B PIK3CA MAP2K2 HRAS
31
Show member pathways
12.89 MAP2K2 HRAS GNAS CTNNB1 BRAF
32
Show member pathways
12.88 TP53 SMAD4 PTEN PIK3CA MAP2K2 HRAS
33
Show member pathways
12.86 PTEN PIK3CA MAP2K2 HRAS BRAF
34 12.86 TP53 MAP2K2 HRAS FGFR3 EGFR BRAF
35
Show member pathways
12.83 TP53 PTEN PIK3CA HRAS FGFR3 EGFR
36
Show member pathways
12.83 PIK3CA MAP2K2 HRAS GNAS FGFR3 EGFR
37
Show member pathways
12.82 TP53 PTEN PIK3CA MAP2K2 HRAS CTNNB1
38
Show member pathways
12.77 PIK3CA MAP2K2 HRAS GNAS EGFR
39
Show member pathways
12.77 MAP2K2 HRAS GNAS EGFR BRAF
40
Show member pathways
12.76 TP53 MAP2K2 HRAS EGFR BRAF
41
Show member pathways
12.76 PIK3CA MAP2K2 HRAS GNAS EGFR CTNNB1
42 12.75 PIK3CA MAP2K2 HRAS FGFR3 EGFR BRAF
43
Show member pathways
12.72 TP53 PTEN PIK3CA MAP2K2 HRAS GNAS
44
Show member pathways
12.7 PTEN PIK3CA MAP2K2 HRAS EGFR
45
Show member pathways
12.69 TP53 PIK3CA HRAS EGFR CTNNB1
46
Show member pathways
12.67 PIK3CA MAP2K2 HRAS GNAS EGFR
47 12.65 TP53 PTEN PIK3CA MAP2K2 HRAS FGFR3
48
Show member pathways
12.65 TP53 PTEN PIK3CA MAP2K2 HRAS FGFR3
49
Show member pathways
12.64 PTEN PIK3CA MAP2K2 HRAS
50
Show member pathways
12.62 PIK3CA HRAS FGFR3 BRAF

GO Terms for Obsolete: Squamous Cell Carcinoma of Head and Neck

Cellular components related to Obsolete: Squamous Cell Carcinoma of Head and Neck according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.93 TP53 SMAD4 PTEN NFE2L2 MAP2K2 ING1
2 cytoplasm GO:0005737 9.73 TP53 SMAD4 PTEN PIK3CA NFE2L2 MAP2K2
3 perinuclear region of cytoplasm GO:0048471 9.65 MAP2K2 HRAS GNAS EGFR CTNNB1
4 cytosol GO:0005829 9.36 TP53 SMAD4 PTEN PIK3CA NFE2L2 MAP2K2

Biological processes related to Obsolete: Squamous Cell Carcinoma of Head and Neck according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 TP53 SMAD4 NFE2L2 HRAS EGFR CTNNB1
2 phosphorylation GO:0016310 10.03 PIK3CA MAP2K2 FGFR3 EGFR BRAF
3 apoptotic process GO:0006915 10.03 TP53 TNFRSF10B PTEN HRAS FGFR3
4 protein phosphorylation GO:0006468 10 PIK3CA MAP2K2 FGFR3 EGFR BRAF
5 negative regulation of apoptotic process GO:0043066 9.97 TP53 PTEN EGFR CTNNB1 BRAF
6 positive regulation of cell proliferation GO:0008284 9.97 PTEN HRAS FGFR3 EGFR CTNNB1
7 response to drug GO:0042493 9.91 TP53 PTEN GNAS CTNNB1
8 positive regulation of gene expression GO:0010628 9.91 TP53 PTEN NFE2L2 HRAS CTNNB1 BRAF
9 negative regulation of gene expression GO:0010629 9.89 TP53 MAP2K2 HRAS CTNNB1
10 heart development GO:0007507 9.88 TP53 PTEN MAP2K2 CTNNB1
11 MAPK cascade GO:0000165 9.88 MAP2K2 HRAS FGFR3 EGFR BRAF
12 cell proliferation GO:0008283 9.85 TP53 SMAD4 PTEN EGFR CTNNB1
13 negative regulation of cell proliferation GO:0008285 9.85 TP53 SMAD4 PTEN ING1 HRAS CTNNB1
14 positive regulation of MAPK cascade GO:0043410 9.81 HRAS FGFR3 CTNNB1
15 response to estradiol GO:0032355 9.8 PTEN EGFR CTNNB1
16 peptidyl-tyrosine phosphorylation GO:0018108 9.8 MAP2K2 FGFR3 EGFR BRAF
17 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 PTEN HRAS FGFR3 EGFR BRAF
18 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.77 PIK3CA EGFR BRAF
19 regulation of cell proliferation GO:0042127 9.72 TP53 SMAD4 EGFR CTNNB1 BRAF
20 positive regulation of transcription, DNA-templated GO:0045893 9.7 TP53 SMAD4 NFE2L2 MAP2K2 ING1 EGFR
21 thymus development GO:0048538 9.69 MAP2K2 CTNNB1 BRAF
22 positive regulation of histone H3-K4 methylation GO:0051571 9.64 SMAD4 CTNNB1
23 trachea formation GO:0060440 9.56 MAP2K2 CTNNB1
24 cellular response to drug GO:0035690 9.56 TP53 NFE2L2 EGFR BRAF
25 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.55 TP53 NFE2L2
26 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.54 TP53 NFE2L2
27 hair follicle placode formation GO:0060789 9.52 GNAS CTNNB1
28 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.13 TP53 MAP2K2 EGFR
29 regulation of axon regeneration GO:0048679 8.8 PTEN MAP2K2 BRAF

Molecular functions related to Obsolete: Squamous Cell Carcinoma of Head and Neck according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
2 identical protein binding GO:0042802 9.91 TP53 SMAD4 PTEN FGFR3 EGFR BRAF
3 kinase activity GO:0016301 9.85 PIK3CA MAP2K2 FGFR3 EGFR BRAF
4 protein phosphatase binding GO:0019903 9.54 TP53 EGFR CTNNB1
5 RNA polymerase II transcription factor binding GO:0001085 9.43 TP53 SMAD4 CTNNB1
6 I-SMAD binding GO:0070411 9.4 SMAD4 CTNNB1
7 nucleotide binding GO:0000166 9.35 MAP2K2 HRAS FGFR3 EGFR BRAF
8 RNA polymerase II activating transcription factor binding GO:0001102 9.33 TP53 NFE2L2 CTNNB1
9 transcription cofactor binding GO:0001221 9.32 TP53 NFE2L2
10 protein tyrosine kinase activity GO:0004713 8.92 MAP2K2 FGFR3 EGFR BRAF

Sources for Obsolete: Squamous Cell Carcinoma of Head and Neck

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....